ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1196 • ACR Convergence 2020

    Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors

    Austin Wheeler1, Gail Kerr2, Ilona Jileaeva3, Asha Krishna4, Bryant England1, Harlan Sayles1, Geoffrey Thiele1, Jill Poole1, Alison Petro1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2Washington DC VA Medical Center, Washington, DC, 3Howard University Hospital, Washington, DC, 4Washington, D.C. VAMC, Washington, DC

    Background/Purpose: Extra-articular manifestations of rheumatoid arthritis (RA), such as nodules and interstitial lung disease (ILD), portend poor outcomes and are more common in men than…
  • Abstract Number: 1212 • ACR Convergence 2020

    Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)

    Peter Taylor1, Bryan Downie2, Emon Elboudwarej2, Sam Kim2, Angie Hertz2, Amer Mirza2, Jeff Siegel3, Rachael Hawtin2 and Jinfeng Liu2, 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City, 3Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active RA. Previously, we…
  • Abstract Number: 1230 • ACR Convergence 2020

    Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis

    Neha Bhaskar1, Lilian Otalora Rojas2, Tara Jehu1, Shazia Beg1 and Neha Bhanusali1, 1University of Central Florida College of Medicine, orlando, 2University of Central Florida HCA Healthcare GME, Orlando

    Background/Purpose: Ancient Eastern medicine has valued the Curcuma longa (turmeric) plant for its powerful medicinal properties. Curcumin is suggested to possess potent anti-inflammatory, antioxidant, antimicrobial,…
  • Abstract Number: 1410 • ACR Convergence 2020

    Resident Memory T Cells Persist in Joints of Anakinra-Treated Mice in Spontaneous Arthritis Model

    Anais Levescot1, Margaret Chang2, Alexandra Wactor1, Rachel Blaustein1, Nathan Nelson-Maney1, Robert Fuhlbrigge3 and Peter Nigrovic4, 1Brigham and Women's Hospital, Boston, MA, 2Boston Children's Hospital, Boston, MA, 3University of Colorado, Denver, CO, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston

    Background/Purpose: Inflammatory arthritis is characterized by chronic inflammation of joints which can be suppressed with immunomodulatory therapy. However, two-thirds of patients will have an arthritis…
  • Abstract Number: 1528 • ACR Convergence 2020

    Filgotinib Inhibits Monocyte Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts

    Takeo Isozaki1, Yuzo Ikari1 and Tsuyoshi Kasama2, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Filgotinib is a selective small molecule inhibitor of JAK 1…
  • Abstract Number: 1572 • ACR Convergence 2020

    Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases

    Tomohiro Kameda1, Shusaku Nakashima1, Masayuki Inoo2, Ikuko Onishi2, Noriyuki Kurata2, Risa Wakiya3, Mai Mahmound Fahmy Mansour1, Koichi Sugihara1, Yusuke Ushio1, Mikiya Kato1, Hiromi Shimada1 and Hiroaki Dobashi1, 1Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, 2Internal Medicine, Utazu hospital, Ayauta-gun, Kagawa, Japan, 3Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan

    Background/Purpose: Lymphoproliferative disorders (LPD) that develop in rheumatoid arthritis (RA) patients treated with MTX (MTX-LPD) is one of the important complications for RA patients. MTX-LPD…
  • Abstract Number: 1715 • ACR Convergence 2020

    Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)

    Orit Schieir1, Glen Hazlewood2, Susan Bartlett3, Marie-France Valois3, Louis Bessette4, Gilles Boire5, Carol Hitchon6, Edward Keystone7, Janet Pope8, Carter Thorne9, Diane Tin9, Vivian Bykerk10 and Canadian Early Arthritis Cohort (CATCH) Investigators11, 1Canadian Early Arthritis Cohort Study, Montreal, Canada, 2University of Calgary, Calgary, AB, Canada, 3McGill University, Montreal, Canada, 4Laval University, Quebec, Canada, 5Universite de Sherbrooke, Sherbrooke, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, 8Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10Hospital for Special Surgery, New York, NY, 11Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Early diagnosis and rapid initiation of DMARDs following a treat-to-target approach have made remission a realizable goal for many persons living with RA. Despite…
  • Abstract Number: 1731 • ACR Convergence 2020

    Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan

    Maxime Verhoeven1, Paco Welsing1, Janneke Tekstra1, Jacob van Laar1, Floris Lafeber1, Johannes Jacobs1 and Anton Westgeest2, 1UMC Utrecht, Utrecht, Netherlands, 2Máxima MC Eindhoven, Eindhoven, Netherlands

    Background/Purpose: Disease activity in rheumatoid arthritis (RA) patients is usually measured by an index like DAS28,1 a composite measure consisting of 28 swollen and/or tender…
  • Abstract Number: 1748 • ACR Convergence 2020

    Effects of Abatacept and Tumor Necrosis Factor Inhibitor on the Normal Glycosylated Hemoglobin Level in Patients with Rheumatoid Arthritis

    Yusuke Miwa1 and Yuko Mitamura2, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Yokohama, Kanagawa, Japan, 2Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Tokyo, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) and diabetes mellitus (DM) are associated with inflammation. Abatacept has been reported to be effective for type 1 diabetes. We aimed…
  • Abstract Number: 1767 • ACR Convergence 2020

    Maternal Peripartum Outcomes Are Similar to the General Population in Rheumatoid Arthritis Pregnancies

    Sarah Tarplin1, Alex Camai1 and April Barnado1, 1Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Data on birth outcomes to women with rheumatoid arthritis (RA) are limited and conflicting. Some studies indicate that women with well controlled RA have…
  • Abstract Number: 1979 • ACR Convergence 2020

    Participant Engagement and Adherence in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported Outcome Data Among Rheumatoid Arthritis Patients

    William Nowell1, Jeffrey R Curtis2, Hong Zhao3, Fenglong Xie3, Laura Stradford4, David Curtis5, Kelly Gavigan4, Jessica Boles4, Justin Owensby3, Cassie Clinton2, Ilya Lipkovich6, Shilpa Venkatachalam7, Sandra Nolot6 and Virginia Haynes6, 1Global Healthy Living Foundation, New York City, NY, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Global Healthy Living Foundation, Upper Nyack, NY, 5Global Healthy Living Foundation, New York City, 6Eli Lilly & Company, Indianapolis, IN, 7Global Healthy Living Foundation, Upper Nyack

    Background/Purpose: Characterization of how different types of patient-generated data reflect patients’ experience is needed to guide integration of electronically collected patient-reported outcome (ePRO) measures and…
  • Abstract Number: 2008 • ACR Convergence 2020

    Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort

    Emilie Sapart1, Tatiana Sokolova1, Stéphanie de Montjoye1, Stéphanie Dierckx2, Adrien Nzeusseu Toukap3, Aleksandra Avramovska1 and Patrick Durez4, 1Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 2Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, 31Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, 4Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

    Background/Purpose: The EULAR recommendations, updated in 20161 and 20192, propose the initiation of glucocorticoid (GC) therapy in combination with cDMARDs background therapy for every patient…
  • Abstract Number: 0033 • ACR Convergence 2020

    Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy

    Matthew Wright1, Mette Kiel Smed2, J Lee Nelson3, Jørn Olsen4, Merete Hetland5, Vibeke Zoffmann2 and Damini Jawaheer6, 1UCSF Children's Hospital Oakland Research Institute, Oakland, CA, 2The Juliane Marie Center, Copenhagen, Denmark, 3Fred Hutchinson Cancer Res Ctr and U of WA, Seattle, WA, 4Aarhus University Hospital, Aarhus, Denmark, 5The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, 6UCSF Benioff Children's Hospital Oakland Research Institute, Oakland, CA

    Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…
  • Abstract Number: 0105 • ACR Convergence 2020

    Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients

    Balázs Juhász1, Katalin Gulyás1, Ágnes Horváth1, Edit Végh1, Anita Pusztai2, Ágnes Szentpétery3, Zsófia Pethő1, Nóra Bodnár1, Attila Hamar1, Levente Bodoki1, Harjit Bhattoa1, Éva Szekanecz1, Katalin Hodosi1, Andrea Domján1, Szilvia Szamosi1, Csaba Horváth4, Sándor Szántó1, Gabriella Szűcs1, Hennie Raterman5, Oliver FitzGerald6 and Zoltán Szekanecz1, 1University of Debrecen, Debrecen, Hungary, 2University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, 3Uppsala University Hospital, Uppsala, Sweden, 4Semmelweis University, Budapest, Hungary, 5Northwest Clinics, Alkmaar, Netherlands, 6Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland

    Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…
  • Abstract Number: 0152 • ACR Convergence 2020

    Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals

    Swathi Reddy1, Aricca Van Citters2, Rashmi Arora1, Kyawt Shwin1, Lisa Johnson2, Jabeen Ahmad2, Guy Eakin3, Eugene Nelson2, Andreas Reimold1 and Salahuddin Kazi1, 1Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, 2The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, 3Arthritis Foundation, Atlanta, GA

    Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…
  • « Previous Page
  • 1
  • …
  • 155
  • 156
  • 157
  • 158
  • 159
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology